| Orexigen: FDA Brings Good News for Obesity Drug Zacks.com submits: Recently Orexigen Therapeutics, Inc. (OREX) received a boost when the US Food and Drug Administration (FDA) accepted the New Drug Application for its candidate Contrave (naltrexone SR/bupropion SR). The candidate, a combination therapy, aims to address physiological and behavioral causes of obesity.The substantial amount of evidence gathered through the Contrave Obesity Research (COR) clinical program formed the basis of the application filed by the company in March 2010. The COR program studied more than 4,500 patients.Complete Story » seekingalpha.com |
Firms Vie for Anthrax Contract Emergent BioSolutions and PharmAthene are in a pitched battle to supply the U.S. government with a next-generation anthrax vaccine. online.wsj.com |
Agreement for LabCorp (Zacks) LabCorp entered into a collaboration agreement with Clearstone Central Laboratories us.rd.yahoo.com |
Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results [Business Wire] - CAMBRIDGE, Mass.----Ironwood Pharmaceuticals, Inc. announced it will host a conference call and webcast today at 6:00 p.m. Eastern Time to discuss the positive top-line results of its Phase 3 clinical trial of linaclotide in patients with irritable bowel syndrome with constipation . us.rd.yahoo.com |
Insight Imaging Completes Sale of Seven Imaging Centers [Business Wire] - InSight Health Services Holdings Corp. today announced that it has completed the previously announced sale of seven imaging centers. Six centers were located in El Paso, Texas and Las Cruces, New Mexico and one imaging center in California. us.rd.yahoo.com |